
ALTERITY THERAPEUTICS LTD
Nasdaq · Pharmaceutical Preparations
Company Overview
A concise company profile alongside the latest public filing activity.
Alterity Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule drug candidates for neurodegenerative diseases, including Parkinson's disease and multiple system atrophy, by targeting toxic iron accumulation and protein aggregation in the brain.
Company profile sourced from SEC filings.
Corporate Insider Trades
Open-market purchases and sales by directors, officers, and other company insiders.
| Insider | Type | Value | Shares / Price | Date |
|---|---|---|---|---|
| Marks Peter AshleyDirector | Buy | $24K | 47,620at $0.50 | Aug 31, 2026 |
Source: SEC EDGAR Form 4 filings
Congressional Trades
Recent disclosures by members of the U.S. House and Senate.
Source: Senate eFD and House Clerk STOCK Act disclosures
Get notable ATHE activity by email
Free alerts for the insider and congressional trades worth watching.
For informational purposes only, not investment advice. Filings can be delayed, corrected, or amended. Trading activity alone does not predict future performance.